期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1073479
关键词
plasma cell dyscrasias; serum; M-protein; MALDI-TOF-MS; screening test
类别
资金
- National Natural Science Foundation of China [82104216]
- Guangdong Basic and Applied Basic Research Foundation [2020A1515011450]
- Shenzhen Project of Science and Technology [JCYJ20190809094007719, JCYJ20190809095203586]
- fund of Sanming Project of Medicine in Shenzhen, China [SZSM201812088]
A new MALDI-TOF Mass spectrometry-based method has been developed for rapid screening of M-proteins in human serum, showing high analytical performance and throughput as a new choice for the diagnosis of plasma cell dyscrasias.
Monoclonal immunoglobin (M-protein) is a serum biomarker for the diagnosis of plasma cell dyscrasias. Despite limitation of analytical sensitivity and resolution, serum protein electrophoresis and immunofixation electrophoresis are still the front-line tests for the detection of M-proteins. Herein, we developed a MALDI-TOF Mass spectrometry-based method for the screening test of M-proteins in human serum. Based on the unique mass signature of different immunoglobin isotypes, M-Proteins could be rapidly identified and typed. The method demonstrated with high analytical performance and throughput, rapid and simple, which could be a new choice for the diagnosis of plasma cell dyscrasias.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据